vs
MAXCYTE, INC.（MXCT）与OneMedNet Corp（ONMD）财务数据对比。点击上方公司名可切换其他公司
MAXCYTE, INC.的季度营收约是OneMedNet Corp的5.4倍（$4.8M vs $890.0K）。MAXCYTE, INC.净利率更高（-200.5% vs -352.8%，领先152.3%）。OneMedNet Corp同比增速更快（3323.1% vs -20.9%）。OneMedNet Corp自由现金流更多（$-1.7M vs $-2.9M）。过去两年OneMedNet Corp的营收复合增速更高（89.4% vs -7.4%）
MaxCyte Inc.是一家全球化生物技术企业，专注于开发细胞工程平台及细胞与基因治疗领域的赋能技术。其专利非病毒细胞修饰系统被制药、生物技术及生命科学研究机构广泛采用，支持免疫疗法、基因编辑疗法及下一代生物药从临床前到商业化的全流程研发。
OneMedNet Corp是一家总部位于美国的医疗科技企业，提供面向医学影像与患者健康信息的安全云数据共享及工作流解决方案，服务覆盖医疗机构、支付方及生命科学领域机构，核心运营市场为北美地区。
MXCT vs ONMD — 直观对比
营收规模更大
MXCT
是对方的5.4倍
$890.0K
营收增速更快
ONMD
高出3344.0%
-20.9%
净利率更高
MXCT
高出152.3%
-352.8%
自由现金流更多
ONMD
多$1.2M
$-2.9M
两年增速更快
ONMD
近两年复合增速
-7.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $4.8M | $890.0K |
| 净利润 | $-9.6M | $-3.1M |
| 毛利率 | — | 20.7% |
| 营业利润率 | -234.5% | -353.4% |
| 净利率 | -200.5% | -352.8% |
| 营收同比 | -20.9% | 3323.1% |
| 净利润同比 | 9.4% | -32.3% |
| 每股收益（稀释后） | — | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MXCTONMD
| Q4 25 | $4.8M | $890.0K | ||
| Q3 25 | $4.6M | $177.0K | ||
| Q2 25 | $5.8M | $155.0K | ||
| Q1 25 | $5.7M | $137.0K | ||
| Q4 24 | $6.1M | $26.0K | ||
| Q3 24 | $5.6M | $142.0K | ||
| Q2 24 | $5.0M | $227.0K | ||
| Q1 24 | $5.6M | $248.0K |
净利润MXCTONMD
| Q4 25 | $-9.6M | $-3.1M | ||
| Q3 25 | $-12.4M | $-741.0K | ||
| Q2 25 | $-12.4M | $3.0M | ||
| Q1 25 | $-10.3M | $-1.9M | ||
| Q4 24 | $-10.6M | $-2.4M | ||
| Q3 24 | $-11.6M | $-2.1M | ||
| Q2 24 | $-9.4M | $-3.6M | ||
| Q1 24 | $-9.5M | $-2.1M |
毛利率MXCTONMD
| Q4 25 | — | 20.7% | ||
| Q3 25 | — | -125.4% | ||
| Q2 25 | — | -155.5% | ||
| Q1 25 | — | -163.5% | ||
| Q4 24 | — | -100.0% | ||
| Q3 24 | — | -59.2% | ||
| Q2 24 | — | -44.9% | ||
| Q1 24 | — | -27.8% |
营业利润率MXCTONMD
| Q4 25 | -234.5% | -353.4% | ||
| Q3 25 | -307.4% | -1262.7% | ||
| Q2 25 | -244.3% | -1331.0% | ||
| Q1 25 | -214.1% | -1623.4% | ||
| Q4 24 | -213.1% | -10438.5% | ||
| Q3 24 | -250.4% | -1645.1% | ||
| Q2 24 | -241.0% | -1081.1% | ||
| Q1 24 | -219.8% | -847.2% |
净利率MXCTONMD
| Q4 25 | -200.5% | -352.8% | ||
| Q3 25 | -269.7% | -418.6% | ||
| Q2 25 | -212.2% | 1923.9% | ||
| Q1 25 | -178.7% | -1388.3% | ||
| Q4 24 | -175.0% | -9126.9% | ||
| Q3 24 | -205.9% | -1449.3% | ||
| Q2 24 | -188.8% | -1581.1% | ||
| Q1 24 | -170.6% | -850.4% |
每股收益（稀释后）MXCTONMD
| Q4 25 | — | $-0.06 | ||
| Q3 25 | $-0.12 | $-0.01 | ||
| Q2 25 | $-0.12 | $0.07 | ||
| Q1 25 | — | $-0.06 | ||
| Q4 24 | — | $-0.07 | ||
| Q3 24 | $-0.11 | $-0.07 | ||
| Q2 24 | $-0.09 | $-0.14 | ||
| Q1 24 | — | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $103.0M | $585.0K |
| 总债务越低越好 | — | $220.0K |
| 股东权益账面价值 | $171.5M | $-3.0M |
| 总资产 | $202.5M | $2.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MXCTONMD
| Q4 25 | $103.0M | $585.0K | ||
| Q3 25 | $105.7M | $149.0K | ||
| Q2 25 | $126.6M | $122.0K | ||
| Q1 25 | $138.3M | $144.0K | ||
| Q4 24 | $154.5M | $172.0K | ||
| Q3 24 | $153.8M | $1.9M | ||
| Q2 24 | $157.3M | $407.0K | ||
| Q1 24 | $157.5M | $174.0K |
总债务MXCTONMD
| Q4 25 | — | $220.0K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $2.3M | ||
| Q4 24 | — | $2.3M | ||
| Q3 24 | — | $2.3M | ||
| Q2 24 | — | $2.4M | ||
| Q1 24 | — | — |
股东权益MXCTONMD
| Q4 25 | $171.5M | $-3.0M | ||
| Q3 25 | $180.3M | $-3.9M | ||
| Q2 25 | $190.7M | $-3.8M | ||
| Q1 25 | $199.4M | $-16.6M | ||
| Q4 24 | $206.3M | $-15.9M | ||
| Q3 24 | $213.3M | $-14.3M | ||
| Q2 24 | $221.3M | $-19.2M | ||
| Q1 24 | $226.4M | $-15.7M |
总资产MXCTONMD
| Q4 25 | $202.5M | $2.2M | ||
| Q3 25 | $213.5M | $1.5M | ||
| Q2 25 | $219.8M | $2.3M | ||
| Q1 25 | $230.0M | $1.7M | ||
| Q4 24 | $239.5M | $3.7M | ||
| Q3 24 | $248.6M | $4.4M | ||
| Q2 24 | $251.5M | $1.0M | ||
| Q1 24 | $257.9M | $750.0K |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.7M | $-1.7M |
| 自由现金流经营现金流 - 资本支出 | $-2.9M | $-1.7M |
| 自由现金流率自由现金流/营收 | -61.0% | -193.0% |
| 资本支出强度资本支出/营收 | 4.8% | 0.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-36.2M | — |
8季度趋势，按日历期对齐
经营现金流MXCTONMD
| Q4 25 | $-2.7M | $-1.7M | ||
| Q3 25 | $-7.5M | $-1.6M | ||
| Q2 25 | $-9.9M | $-2.3M | ||
| Q1 25 | $-14.4M | $-1.9M | ||
| Q4 24 | $-7.8M | $-2.0M | ||
| Q3 24 | $-4.4M | $-1.9M | ||
| Q2 24 | $-4.8M | $-1.5M | ||
| Q1 24 | $-10.6M | $-1.5M |
自由现金流MXCTONMD
| Q4 25 | $-2.9M | $-1.7M | ||
| Q3 25 | $-7.8M | — | ||
| Q2 25 | $-10.4M | $-2.3M | ||
| Q1 25 | $-15.1M | $-2.0M | ||
| Q4 24 | $-8.0M | $-2.0M | ||
| Q3 24 | $-4.8M | $-1.9M | ||
| Q2 24 | $-5.1M | $-1.5M | ||
| Q1 24 | $-11.4M | $-1.6M |
自由现金流率MXCTONMD
| Q4 25 | -61.0% | -193.0% | ||
| Q3 25 | -168.5% | — | ||
| Q2 25 | -179.2% | -1475.5% | ||
| Q1 25 | -262.3% | -1425.5% | ||
| Q4 24 | -131.6% | -7811.5% | ||
| Q3 24 | -85.5% | -1346.5% | ||
| Q2 24 | -103.3% | -663.9% | ||
| Q1 24 | -203.6% | -626.2% |
资本支出强度MXCTONMD
| Q4 25 | 4.8% | 0.6% | ||
| Q3 25 | 6.5% | 0.0% | ||
| Q2 25 | 10.0% | 1.9% | ||
| Q1 25 | 11.4% | 3.6% | ||
| Q4 24 | 2.4% | 134.6% | ||
| Q3 24 | 7.2% | 6.3% | ||
| Q2 24 | 5.9% | 0.4% | ||
| Q1 24 | 14.4% | 2.4% |
现金转化率MXCTONMD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.77× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
